Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of clozapine in treatment-resistant schizophrenia has completed, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Clozapine (Clozapine)

Snippet

Sponsor: Novartis | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED